Overcome market access challenges with case studies from MSD, Sanofi and GSK | European Pharmaceutical Pricing and Reimbursement

SMi's 21st annual European Pharmaceutical Pricing and Reimbursement conference, taking place on the 5th - 6th October 2015 in London, will address complex market access challenges and details how to overcome them with case studies from MSD, Sanofi, GSK and more. End Quote

(1888PressRelease) September 09, 2015 - SMi's 21st annual European Pharmaceutical Pricing and Reimbursement conference will provide the ideal platform for payers and other decision makers from both public and private organisations, to benchmark with peers internationally and provide pharma companies with an invaluable insight into the decision making processes and approaches of vital stakeholders. The two-day conference programme will help further your understanding and enable you to develop best practice approaches to complex market access challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications though case studies led by GSK, Sanofi, MSD and more who will be presenting at the two-day event.

Furthermore, we are delighted to announce that Day 2 will feature a new panel discussion titled "PharmaDiplomacy: A Proposal for a Collaborative, Mutually Acceptable Approach to Drug Pricing" with GSK, Meteos and the Belgian National Institute for Health and Disability Insurance discussing:
• How far stakeholder discussion and collaboration at regular points along the drug development pathway can contribute to mutually acceptable pricing agreements.
• 'Checklist for Collaborative, Mutually Acceptable Drug Pricing'. This consultation document was created by the PharmaDiplomacy team - a group of senior representatives from industry and the health systems in the United States and Europe, convened by think tank, Meteos. The 'Checklist' identifies concrete steps along the pharmaceutical development pathway which offer an opportunity to establish a more collaborative, systematic approach to defining value and pricing.
• The panel will be made up of payer and industry representatives who have been involved in the development of the 'Checklist'. The audience will also be invited to share their thoughts and input on the document, which is currently under consultation.

WHO WILL YOU MEET?
Confirmed attendees include: Apex Healthcare Consulting Limited, Association of the British Pharmaceutical Industry (ABPI), Belgian National Institute for Health and Disability Insurance, DM Pharma Issues, Ethical Medicines Industry Group (EMIG), European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Fieldfisher, German Pharmaceutical Industry Association, GSK, Hospira UK, Imperial College London, Ipsen, Kowa Pharmaceutical Europe Co. Ltd., MArS Market Access & Pricing Strategy UG, MSD, Meteos, Myeloma UK, NHS Commercial Solutions, Northumbria NHS Foundation Trust, Quintiles (UK) Ltd, Sanofi , The National Pharmaceutical Association Ltd, University of Ferrara plus more...

To view the full speaker line-up and complete two-day conference programme, visit http://www.pharmaceuticalpricing.co.uk/1888pressrelease

###

space

Other Related Press Releases